Kuros Bioscience GAAP EPS of -$0.05, revenue of $63.48M misses by $19.35M; reaffirms FY outlook

* Kuros Bioscience press release [https://seekingalpha.com/pr/20200493-kuros-biosciences-reports-first-half-of-2025-results] (OTCPK:CSBTF [https://seekingalpha.com/symbol/CSBTF]): 1H GAAP EPS of -$0.05.
* Revenue of $63.48M (+77.9% Y/Y) misses by $19.35M.
* Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million)
* Direct MagnetOs™ sales increased by 77% to USD 62.7 million in H1 2025 (H1 2024: USD 35.4 million).
* Total Group EBITDA reached USD 5.1 million in H1 2025 (H1 2024: USD 0.8 million) and total Group adjusted EBITDA* amounted to USD 7.8 million in H1 2025, equaling a margin of 12.3% (H1 2024: USD 4.5 million at 12.6%).
* The Group continues to expect sales growth of at least 60% in 2025 and anticipates sales of between USD 220 million and USD 250 million by 2027.

MORE ON KUROS BIOSCIENCE

* Historical earnings data for Kuros Bioscience [https://seekingalpha.com/symbol/CSBTF/earnings]
* Financial information for Kuros Bioscience [https://seekingalpha.com/symbol/CSBTF/income-statement]